Declaratory Orders For Drug Firms Could Come Easier With High Court Ruling
This article was originally published in The Tan Sheet
Executive Summary
The first application of a recent Supreme Court decision which appears to ease the way for declaratory judgment actions by ANDA filers could come in a case brought by Teva against Novartis regarding Famvir
You may also be interested in...
Court Tweaks ANDA Suit Standards, May Widen Declaratory Judgment Window
The parameters under which generic drug firms can seek declaratory judgments against patent holders could be expanded in a March 30 ruling by the U.S. Court of Appeals for the Federal Circuit
Court Tweaks ANDA Suit Standards, May Widen Declaratory Judgment Window
The parameters under which generic drug firms can seek declaratory judgments against patent holders could be expanded in a March 30 ruling by the U.S. Court of Appeals for the Federal Circuit
Court Tweaks ANDA Suit Standards, May Widen Declaratory Judgment Window
The parameters under which generic drug firms can seek declaratory judgments against patent holders could be expanded in a March 30 ruling by the U.S. Court of Appeals for the Federal Circuit